Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (121-130 of 247) with videos related to

Pageof 25
Sort By:
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Cancer|June 22, 2010
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
Breast Cancer Research and Treatment|October 13, 2015
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research InstituteDenise A Yardley, Linda D Bosserman, Joyce A O'Shaughnessy, et al.
Clinical Pharmacology in Drug Development|May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid TumorsGeoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Clinical Lung Cancer|May 5, 2010
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, Dana S Thompson, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan plus carboplatin in two dose schedulesSuzanne F Jones, Howard A Burris, John D Hainsworth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2011
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Clinical Lung Cancer|June 10, 2005
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancerSuzanne F Jones, John G Kuhn, F Anthony Greco, et al.
The Journal of Clinical Investigation|August 31, 2021
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19Shanna A Arnold Egloff, Angela Junglen, Joseph Sa Restivo, et al.
Pageof 25

Showing results (121-130 of 247) with videos related to

Sort By:
Pageof 25
Investigational New Drugs|March 1, 2016
A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid tumorsJeffrey R Infante, David S Mendelson, Howard A Burris, et al.
Cancer|June 22, 2010
Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research ConsortiumJohn D Hainsworth, Jeffrey R Infante, David R Spigel, et al.
Breast Cancer Research and Treatment|October 13, 2015
Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research InstituteDenise A Yardley, Linda D Bosserman, Joyce A O'Shaughnessy, et al.
Clinical Pharmacology in Drug Development|May 26, 2018
Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid TumorsGeoffrey I Shapiro, Rebecca S Kristeleit, Howard A Burris, et al.
Clinical Lung Cancer|May 5, 2010
Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancerDavid R Spigel, F Anthony Greco, Dana S Thompson, et al.
Oncology (Williston Park, N.Y.)|June 13, 2003
Phase I. Trial of irinotecan plus carboplatin in two dose schedulesSuzanne F Jones, Howard A Burris, John D Hainsworth, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 9, 2011
A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancerDavid R Spigel, John D Hainsworth, Dianna L Shipley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 14, 2011
Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumorsJohanna C Bendell, Jordi Rodon, Howard A Burris, et al.
Clinical Lung Cancer|June 10, 2005
A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancerSuzanne F Jones, John G Kuhn, F Anthony Greco, et al.
The Journal of Clinical Investigation|August 31, 2021
Convalescent plasma associates with reduced mortality and improved clinical trajectory in patients hospitalized with COVID-19Shanna A Arnold Egloff, Angela Junglen, Joseph Sa Restivo, et al.
Pageof 25